Key points are not available for this paper at this time.
Abstract Background: Colorectal cancer (CRC) is the third most common cancer worldwide, with almost 2 million new cases reported in 2020. CRC develops over time from a pre-cancerous stage (adenoma) - the ‘adenoma-carcinoma sequence’. Pre-cancerous lesions, such as Higher Risk Adenomas (HRA), harbour an increased risk of developing into CRC and their features are defined according to size, number and histological features. Screening for signs of CRC is recommended for average-risk adults using faecal immunochemical testing (FIT) in the UK, to enable the removal of pre-cancerous lesions and treatment of early-stage cancers. However, the performance of FIT is limited. Approximately 10% of CRC diagnoses have a negative FIT result, and it currently has ~93% false positive rate. Moreover, the sensitivity for detecting AA is only 24%, highlighting the need for alternative strategies. Methods: A promising strategy for earlier CRC detection is the clinical use of Fourier transform infrared (FTIR) spectroscopy. The Dxcover® Colorectal Cancer Liquid Biopsy is a rapid multi-omic test that interrogates a blood sample with infrared (IR) radiation and produces a distinctive signature that represents the whole biomolecular profile of the sample. Rather than focusing on individual biomarkers, the technique encompasses the full range of diagnostic information from both the tumor and the non-tumor response. In the initial CREATE (ColoREctal Cancer Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 7294.
Cameron et al. (Fri,) studied this question.